Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Elizabeth Redente to Pulmonary Fibrosis

This is a "connection" page, showing publications Elizabeth Redente has written about Pulmonary Fibrosis.

 
Connection Strength
 
 
 
3.555
 
  1. Cooley JC, Redente EF. Getting the Timing Right: Controlling BCL-2 Inhibition as an Antifibrotic Therapy. Am J Respir Cell Mol Biol. 2024 Apr; 70(4):231-232.
    View in: PubMed
    Score: 0.676
  2. Redente EF. How Do We Know What We Are Missing? Loss of Signaling through CD148 Drives Fibroblast Activation in Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 08 01; 204(3):249-251.
    View in: PubMed
    Score: 0.562
  3. Guzy R, Redente EF. Kindlin for the Fire: Targeting Proline Synthesis to Extinguish Matrix Production in Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2021 07; 65(1):4-5.
    View in: PubMed
    Score: 0.559
  4. Redente EF. ABC Transporters: An Overlooked Mechanism of Drug Failure in Our Preclinical Models? Am J Respir Cell Mol Biol. 2020 02; 62(2):130-131.
    View in: PubMed
    Score: 0.507
  5. Redente EF, Jacobsen KM, Solomon JJ, Lara AR, Faubel S, Keith RC, Henson PM, Downey GP, Riches DW. Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol. 2011 Oct; 301(4):L510-8.
    View in: PubMed
    Score: 0.280
  6. King EM, Zhao Y, Moore CM, Steinhart B, Anderson KC, Vestal B, Moore PK, McManus SA, Evans CM, Mould KJ, Redente EF, McCubbrey AL, Janssen WJ. Gpnmb and Spp1 mark a conserved macrophage injury response masking fibrosis-specific programming in the lung. JCI Insight. 2024 Dec 20; 9(24).
    View in: PubMed
    Score: 0.178
  7. O'Callaghan M, Tarling EJ, Bridges JP, Redente EF, Byrne AJ, Keane MP, McCarthy C. Reexamining the Role of Pulmonary Lipids in the Pathogenesis of Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2024 Oct; 71(4):407-419.
    View in: PubMed
    Score: 0.175
  8. Ting C, Konopka K, Benedeck RE, Riches DWH, Redente EF, Oldham JM, Zemans RL. Biomarkers Unveil Insights into Pathology of Transitional Epithelial States in Pulmonary Fibrosis. Am J Respir Crit Care Med. 2024 Sep 01; 210(5):687-690.
    View in: PubMed
    Score: 0.174
  9. McCubbrey AL, Barthel L, Mohning MP, Redente EF, Mould KJ, Thomas SM, Leach SM, Danhorn T, Gibbings SL, Jakubzick CV, Henson PM, Janssen WJ. Deletion of c-FLIP from CD11bhi Macrophages Prevents Development of Bleomycin-induced Lung Fibrosis. Am J Respir Cell Mol Biol. 2018 01; 58(1):66-78.
    View in: PubMed
    Score: 0.110
  10. Aschner Y, Khalifah AP, Briones N, Yamashita C, Dolgonos L, Young SK, Campbell MN, Riches DW, Redente EF, Janssen WJ, Henson PM, Sap J, Vacaresse N, Kapus A, McCulloch CA, Zemans RL, Downey GP. Protein tyrosine phosphatase a mediates profibrotic signaling in lung fibroblasts through TGF-? responsiveness. Am J Pathol. 2014 May; 184(5):1489-502.
    View in: PubMed
    Score: 0.084
  11. Trivedi R, Redente EF, Thakur A, Riches DW, Kompella UB. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology. 2012 Dec 21; 23(50):505101.
    View in: PubMed
    Score: 0.077
  12. Keith RC, Powers JL, Redente EF, Sergew A, Martin RJ, Gizinski A, Holers VM, Sakaguchi S, Riches DW. A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice. Exp Lung Res. 2012 Mar; 38(2):55-66.
    View in: PubMed
    Score: 0.072
  13. Wynes MW, Edelman BL, Kostyk AG, Edwards MG, Coldren C, Groshong SD, Cosgrove GP, Redente EF, Bamberg A, Brown KK, Reisdorph N, Keith RC, Frankel SK, Riches DW. Increased cell surface Fas expression is necessary and sufficient to sensitize lung fibroblasts to Fas ligation-induced apoptosis: implications for fibroblast accumulation in idiopathic pulmonary fibrosis. J Immunol. 2011 Jul 01; 187(1):527-37.
    View in: PubMed
    Score: 0.069
  14. Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019 09; 54(3).
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)